peppersite
Regenerative supportsubcutaneoustopical

GHK-Cu

GHK-Cu, or copper tripeptide-1, is a natural peptide of three amino acids bound to a copper ion, found in human blood plasma. It is studied for skin, hair and wound repair, mostly in cells and animals, with the strongest human evidence for topical use.

Researched for
Tissue RepairInflammationLongevityRecoveryPost-Procedure Recovery

At a glance

Type
Regenerative support
Given by
subcutaneous, topical
Evidence
AnimalAnimal, across 1 audit
Reported amount
1 mg per Peptide Dosing Protocols. All 4 sources
Typical vial
50 mg in 2 mL

How much to draw

Full calculator →
Your draw
4units
0.04 mL on a U-100 insulin syringe
25 mg/mL50 doses per vial
Vial size:
Amount per dose

Opened on 1 mg, the figure Peptide Dosing Protocols reports for GHK-Cu, and a 50 mg vial in 2 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for GHK-Cu or for anything else, and nothing below has been checked against the study it came from.

1-2 mg SC daily, or topical application
Frequency
once daily30-day cycles · 30-day cycles
Route
subcutaneous or topical
Reported by
Commonly published practitioner dosing range - provider confirmation required.
Topical: 0.01-1% in cream/serum; SC injection: 1-2 mg daily
Frequency
Topical: once or twice daily; SC: once dailyRepeatable
Route
subcutaneous or oral or topical
Reported by
Peptide Protocol Wiki
Standard: 1.0-1.5 mg · Low: 1.0 mg · High: 2.0 mg
Frequency
Daily4-6 weeks · 4-8 weeks
Route
Subcutaneous injection
Reported by
Peptide Dosing Protocols
What it saysThe standard dosing for GHK-Cu is 1.0-1.5 mg daily for 4-6 weeks.
Topical: serum to face and neck twice daily (AM and PM) after cleansing, before moisturizer. Injectable referenced at 200-300 mcg (0.2-0.3 mg) before bedtime in recovery contexts; sterile technique and supervision stressed. Microneedling before topical cited to enhance absorption.
Frequency
Topical 2x daily; injectable nightly in recovery contexts · Topical AM/PM; injectable before bed
Route
topical or subcutaneous
Reported by
Peptide Therapy Reference Text
What it saysAug 2026), secondary reference; provider confirmation required.
Reconstitution, as reported
  • Commonly 50 mg vials (injectable) or topical formulations · Reconstitute with bacteriostatic water (injectable)
  • Bacteriostatic water
  • 50 mg vial reconstituted with 2.0 mL bacteriostatic water
Watch first
1:34
0:001:34

You have probably already touched this one without knowing. It is the peptide that actually crossed over onto real shelves.

What our audits found

How it is thought to work

GHK-Cu does two things at once: it carries copper into cells where copper-dependent enzymes need it, and the peptide part itself changes how repair genes behave in skin cells. Researchers link it to collagen and elastin production in dermal fibroblasts, to more decorin, a small molecule that helps keep collagen organised, and to shifts in matrix metalloproteinases and their inhibitors. Blood levels fall from roughly 200 ng/mL around age 20 to about 80 ng/mL by age 60, which is part of why it became a research target. Most of this comes from cell and animal models, and no published human randomised trial has looked at long-term injected GHK-Cu.

In technical termsCopper-binding peptide with repair signaling.

What we don't know

Injection: no published human randomized trial has evaluated long-term injectable GHK-Cu for skin, hair or wound outcomes. Systemic effects from injection are not well characterised in published trials.

Human trials overall: the strongest human evidence is for topical use. Reviews covered in our audit say human trial data are limited and comprehensive randomized controlled trials are lacking.

Cancer and copper: effects in active cancer are not well characterised. Whether long-term or frequent use lets copper build up is a theoretical question that has not been answered.

Comparison with KPV: no study has tested the two in the same model with the same endpoints, and no test of the two together has been published.

Reported side effects

Seen in studies: topical GHK-Cu has a long cosmetic safety record, and the skin effects reported in that work are mild and local.

Reported by users: with creams, redness, tingling, dryness or passing irritation, more common above 4% strength and when it is layered with strong retinoids or low-pH acids. With injection, redness, mild swelling, brief warmth, or a faintly blue-tinted bruise from the copper.

Not ruled out: systemic effects from injection are rare in user reports but not well characterised in published trials. Long-term or frequent use raises a theoretical question about copper building up, and since GHK-Cu drives both collagen building and the enzymes that break collagen down, unbalanced use could in principle disturb the tissue matrix. Purity, copper content and stability vary between research vials.

Who should avoid it

People who are pregnant or breastfeeding: GHK-Cu has not been adequately studied in pregnancy or lactation, by either route.

People with active cancer or untreated solid tumors: GHK-Cu affects blood-vessel growth and gene expression, and its effects in active cancer are not well characterised.

People with Wilson's disease or another copper-handling disorder: GHK-Cu delivers copper the body can absorb.

People allergic to copper: rare, but possible, which is why sources describe patch-testing a small area first.

People with an active skin infection where it would be applied or injected: the reference describes waiting until the area has healed.

What gets monitored

No specific bloodwork or monitoring schedule is stated. (reported by Peptide Dosing Protocols)

Regulatory status

FDA approval: GHK-Cu is not an FDA-approved drug. The reference entry says it appears in cosmetic products, not as an approved medicine.

Supply: research vials vary in purity, copper content and stability. A review covered in our audit flags unregulated sourcing for formulation variability and sterility.

Checked: November 2026.

Common questions

What is GHK-Cu?

GHK-Cu is a small peptide of three amino acids, glycine, histidine and lysine, bound to a copper ion. It occurs naturally in human plasma, and levels fall with age.

Is GHK-Cu FDA-approved?

No. GHK-Cu is not an FDA-approved drug. It appears in cosmetic products rather than as an approved medicine.

What amounts of GHK-Cu are reported in research planning?

Reported amounts and schedules for GHK-Cu differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

Is GHK-Cu better studied topically or by injection?

Topical use has the stronger evidence base, especially for skin endpoints. No published human randomised trial has looked at long-term injected GHK-Cu.

How is GHK-Cu reconstituted?

That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.

What are the main side effects of GHK-Cu?

Topical effects are usually mild and local: redness, tingling, dryness or passing irritation. Injectable use adds local swelling, warmth or a faintly blue bruise, and systemic effects are not well characterised.

How long did topical studies run before measuring results?

Topical trials measured skin endpoints at 8-12 weeks. A 2023 study in 21 women reported an average 28% increase in skin collagen density at 3 months.

Is GHK-Cu combined with BPC-157 and TB-500?

Yes, those three are the compounds sold together as the GLOW blend. No published human trial has tested the three combined.

Sources

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things
Glutathione

Glutathione (GSH) is a small molecule built from three amino acids, cysteine, glycine and glutamate, made by nearly every cell and most of all by the liver. It has been studied in people for skin lightening, liver enzymes in fatty liver disease, and Parkinson's disease.

Thymosin Alpha-1

Thymosin Alpha-1 (TA1) is a lab-made copy of a 28-amino-acid peptide that the thymus gland makes naturally. It is studied mostly in people as an immune treatment, and is approved in more than 35 countries for chronic hepatitis B, chronic hepatitis C and as an add-on in cancer care.

BPC-157

BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.

GLOW

GLOW is a combination sold as one vial, pairing three peptides: GHK-Cu, BPC-157 and TB-500. It is studied for skin quality, tissue repair and recovery, though no trial has tested the three together in people.

LL-37

LL-37 is the active 37-amino-acid piece of the only known human cathelicidin, a natural germ-fighting protein made by white blood cells, skin cells and other tissue linings. It is studied in antimicrobial and innate-immunity research.

MOTS-c

MOTS-c is a short chain of 16 amino acids that cells build from mitochondrial DNA rather than from the DNA in the nucleus. Most of what is known about it comes from cell and animal work on metabolism, exercise capacity and insulin sensitivity.